Please ensure Javascript is enabled for purposes of website accessibility

Pfizer and BioNTech's COVID-19 Vaccine Authorized by the FDA for Adolescents

By Brian Orelli, PhD - Updated May 11, 2021 at 3:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Parents are pleased, but the move won't change much for the drug companies from a financial perspective.

In a widely expected move, the Food and Drug Administration has expanded its emergency use authorization for Pfizer (PFE 1.17%) and BioNTech's (BNTX 0.21%) COVID-19 vaccine to include people as young as 12 years old.

The widened authorization for BNT162b2 was based on the ability of the vaccine to induce the production of COVID-19 antibodies; the levels of antibodies it generated in clinical trial participants ages 12 through 15 were at least as good as the antibody levels in participants in the 16-to-25 age range.

Those antibodies appear to protect patients from being infected by the coronavirus.

Measured starting one week after they received their second doses of BNT162b2, none of the 1,005 adolescents who were inoculated developed COVID-19. Among the 978 trial participants who received placebo shots, there were 16 cases of COVID-19. That equates to a finding of 100% protection, although the numbers in the study were relatively small.

Healthcare worker giving an injection into the shoulder of a patient

Image source: Getty Images.

The side effect profile for the adolescents was similar to that seen in those 16 and older. In both groups, people had more side effects after the second dose than the first dose.

Pfizer and BioNTech beat Moderna (MRNA -2.60%) to the finish line in terms of gaining FDA authorization for their vaccine to be administered to adolescents. However, BNT162b2's period of exclusivity in that demographic, which presumably will only last for a couple of months, isn't likely to be much of a financial advantage. Large sales contracts with the U.S. government are already in place for both mRNA vaccines, so opening the use of BNT162b2 to a wider age group won't increase its sales. Until another vaccine is authorized for adolescents, some of Pfizer's doses will be used for adolescents, and any supply tightening that might cause for the adult demographic will be filled by Moderna's vaccine or Johnson & Johnson's.

Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$49.15 (1.17%) $0.57
Moderna, Inc. Stock Quote
Moderna, Inc.
$146.10 (-2.60%) $-3.90
BioNTech SE Stock Quote
BioNTech SE
$147.92 (0.21%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.